...
首页> 外文期刊>BMC Medical Genomics >The clinical benefit of array-based comparative genomic hybridization for detection of copy number variants in Czech children with intellectual disability and developmental delay
【24h】

The clinical benefit of array-based comparative genomic hybridization for detection of copy number variants in Czech children with intellectual disability and developmental delay

机译:基于阵列的比较基因组杂交技术在捷克智障和发育迟缓儿童中检测拷贝数变异的临床益处

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Chromosomal microarray analysis has been shown to be a valuable and cost effective assay for elucidating copy number variants (CNVs) in children with intellectual disability and developmental delay (ID/DD). In our study, we performed array-based comparative genomic hybridization (array-CGH) analysis using oligonucleotide-based platforms in 542 Czech patients with ID/DD, autism spectrum disorders and multiple congenital abnormalities. Prior to the array-CGH analysis, all the patients were first examined karyotypically using G-banding. The presence of CNVs and their putative derivation was confirmed using fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA) and predominantly relative quantitative polymerase chain reaction (qPCR). In total, 5.9% (32/542) patients were positive for karyotypic abnormalities. Pathogenic/likely pathogenic CNVs were identified in 17.7% of them (96/542), variants of uncertain significance (VOUS) were detected in 4.8% (26/542) and likely benign CNVs in 9.2% of cases (50/542). We identified 6.6% (36/542) patients with known recurrent microdeletion (24 cases) and microduplication (12 cases) syndromes, as well as 4.8% (26/542) patients with non-recurrent rare microdeletions (21 cases) and microduplications (5 cases). In the group of patients with submicroscopic pathogenic/likely pathogenic CNVs (13.3%; 68/510) we identified 91.2% (62/68) patients with one CNV, 5.9% (4/68) patients with two likely independent CNVs and 2.9% (2/68) patients with two CNVs resulting from cryptic unbalanced translocations. Of all detected CNVs, 21% (31/147) had a de novo origin, 51% (75/147) were inherited and 28% (41/147) of unknown origin. In our cohort pathogenic/likely pathogenic microdeletions were more frequent than microduplications (69%; 51/74 vs. 31%; 23/74) ranging in size from 0.395?Mb to 10.676?Mb (microdeletions) and 0.544?Mb to 8.156?Mb (microduplications), but their sizes were not significantly different (P?=?0.83). The pathogenic/likely pathogenic CNVs (median 2.663?Mb) were significantly larger than benign CNVs (median 0.394?Mb) (P??0.00001) and likewise the pathogenic/likely pathogenic CNVs (median 2.663?Mb) were significantly larger in size than VOUS (median 0.469?Mb) (P??0.00001). Our results confirm the benefit of array-CGH in the current clinical genetic diagnostics leading to identification of the genetic cause of ID/DD in affected children.
机译:染色体微阵列分析已被证明是一种用于阐明智障和发育迟缓(ID / DD)儿童的拷贝数变异(CNV)的有价值且具有成本效益的测定方法。在我们的研究中,我们使用基于寡核苷酸的平台对542例ID / DD,自闭症谱系障碍和多种先天性异常的捷克患者进行了基于阵列的比较基因组杂交(array-CGH)分析。在进行阵列CGH分析之前,首先使用G显带对所有患者进行核型分析。使用荧光原位杂交(FISH),多重连接依赖探针扩增(MLPA)和主要相对定量聚合酶链反应(qPCR)确认了CNV的存在及其推定派生。总共有5.9%(32/542)患者的核型异常为阳性。在其中有17.7%(96/542)中鉴定出了致病性/可能致病性CNV,在4.8%(26/542)中检出了不确定显着性(VOUS)变异,在9.2%的病例中检出了良性CNV(50/542)。我们确定了6.6%(36/542)例复发性微缺失(24例)和微重复(12例)综合征患者,以及4.8%(26/542)例非复发性罕见微缺失(21例)和微重复( 5例)。在亚显微致病性/可能致病性CNV患者组中(13.3%; 68/510),我们确定91.2%(62/68)患者具有1个CNV,5.9%(4/68)患者具有2个独立CNV和2.9% (2/68)因隐秘的不平衡易位而产生两个CNV的患者。在所有检测到的CNV中,有21%(31/147)是从头起源的,有51%(75/147)是遗传的,有28%(41/147)的起源是未知的。在我们的队列中,致病/可能致病的微缺失比微重复更为频繁(69%; 51/74对31%; 23/74),大小从0.395?Mb到10.676?Mb(微缺失),从0.544?Mb到8.156?Mb。 Mb(微复制),但是它们的大小没有显着差异(P = 0.83)。致病/可能致病的CNV(中位数为2.663?Mb)明显大于良性CNV(中位数为0.394?Mb)(P 0.00001),同样,致病/可能致病的CNV(中位数为2.663?Mb)明显更大比VOUS(中位数0.469?Mb)(P 0.00001)。我们的结果证实了array-CGH在当前临床遗传学诊断中的优势,从而可以确定患病儿童ID / DD的遗传原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号